Navigation Links
Nanoparticles used in common household items caused genetic damage in mice
Date:11/16/2009

Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.

The TiO2 nanoparticles induced single- and double-strand DNA breaks and also caused chromosomal damage as well as inflammation, all of which increase the risk for cancer. The UCLA study is the first to show that the nanoparticles had such an effect, said Robert Schiestl, a professor of pathology, radiation oncology and environmental health sciences, a Jonsson Cancer Center scientist and the study's senior author.

Once in the system, the TiO2 nanoparticles accumulate in different organs because the body has no way to eliminate them. And because they are so small, they can go everywhere in the body, even through cells, and may interfere with sub-cellular mechanisms.

The study appears this week in the journal Cancer Research.

In the past, these TiO2 nanoparticles have been considered non-toxic in that they do not incite a chemical reaction. Instead, it is surface interactions that the nanoparticles have within their environment- in this case inside a mouse - that is causing the genetic damage, Schiestl said. They wander throughout the body causing oxidative stress, which can lead to cell death.

It is a novel mechanism of toxicity, a physicochemical reaction, these particles cause in comparison to regular chemical toxins, which are the usual subjects of toxicological research, Schiestl said.

"The novel principle is that titanium by itself is chemically inert. However, when the particles become progressively smaller, their surface, in turn, becomes progressively bigger and in the interaction of this surface with the environment oxidative stress is induced," he said. "This is the first comprehensive study of titanium dioxide nanoparticle-induced genot
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Behavior modification could ease concerns about nanoparticles
2. Knocking nanoparticles off the socks
3. Clemson bioengineer uses nanoparticles to target drugs
4. Therapeutic nanoparticles give new meaning to sugar-coating medicine
5. Carbon nanoparticles toxic to adult fruit flies but benign to young
6. New insights into health and environmental effects of carbon nanoparticles
7. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
8. University of Leicester researchers discover new fluorescent silicon nanoparticles
9. New nanoparticles could revolutionize therapeutic drug discovery
10. Shape matters in the case of cobalt nanoparticles
11. To fight drug addiction, UB researchers target the brain with nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... may soon be a boon to biofuels producers. The ... a surprisingly minimal repertoire of genes that it employs ... further improvements in enzymes customized for biofuels production. ... Biotechnology by a team of government, academic, and industry ...
... the public and the scientific community for access to ... copyright policy to allow authors to retain the rights ... which became effective May 1, applies to all three ... The Journal of Experimental Medicine and The Journal of ...
... (May 2, 2008)As the westernization of India accelerates, tobacco advertising ... urban Indian children as young as 11, according to a ... Public Health. , The study, Associations Between Tobacco Marketing ... the May/June issue of the American Journal of Health Behavior. ...
Cached Biology News:Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 2Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 3Rockefeller University Press allows authors to retain copyright to their published work 2UT researchers find link between advertising and increased tobacco use among India's youth 2UT researchers find link between advertising and increased tobacco use among India's youth 3
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 15 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... sale of shares of convertible preferred stock pursuant to a ... proceeds of approximately $2 million. The preferred stock is convertible ... the investor at a price of $0.1105 per share. , ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... endocrine therapy and oncology, today reported that patient follow-up ... Phase 3 program in benign prostatic hyperplasia (BPH) with ... be completed at the end of this week. Therefore, ...
... Inc., an award-winning developer of Microfluidics and Live ... its cellTRAY Imaging System and cellTRAY Fluidics System ... Imaging and Fluidics Systems provide solutions to a ... reproductive technology (ART), stem cell research, and cryobiology, ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Request Info...
...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: